We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Two Serodiagnostic Tests Compared for Loiasis in Non-Endemic Area

By LabMedica International staff writers
Posted on 18 Jun 2020
Print article
Image: The Loa Antibody Rapid Test detects human IgG against a 148-aminoacid sequence of Ll-SXP-1 (Photo courtesy of Drugs & Diagnostics for Tropical Diseases).
Image: The Loa Antibody Rapid Test detects human IgG against a 148-aminoacid sequence of Ll-SXP-1 (Photo courtesy of Drugs & Diagnostics for Tropical Diseases).
Loiasis, the disease caused by the infection with the filarial nematode Loa loa, is transmitted through the bite of tabanid flies of the genus Chrysops. It is endemic in Central and West Africa where, according to the most recent estimates, about 10 million people are infected.

There is a scarcity of convenient, commercial diagnostics for L. loa. Microscopy requires trained personnel and has low sensitivity, while the serodiagnosis is currently not standardized. Individual case management is also important in non-endemic countries to treat migrants, expatriates and tourists.

Scientists at the Sacro Cuore Don Calabria Hospital (Verona, Italy) retrospectively compared the performance of an Antibody Rapid Test (RDT) and a commercial ELISA pan-filarial test on 170 patients, 65 with loiasis [8 with eyeworm, 29 with positive microfilaremia, 28 with neither microfilaremia nor history of eyeworm but eosinophilia and history of Calabar swelling (probable loiasis)], 95 with other common parasitic infections and no previous exposure to L. loa (37 with M. perstans, one with Brugia sp., 18 with strongyloidiasis, 20 with schistosomiasis, five with hookworm, four with Ascaris lumbricoides infection, 10 with hyper-reactive malarial splenomegaly), and 10 uninfected controls.

The Loa Antibody Rapid Test (RDT, Drugs & Diagnostics for Tropical Diseases, San Diego, CA, USA) detects human IgG against a 148-aminoacid sequence of Ll-SXP-1, a protein with 51–53% sequence identity with Wuchereria bancrofti and Onchocerca volvulus, the two most clinically relevant filarial species. The commercial ELISA kit uses Acanthocheilonema viteae antigens (Bordier Affinity Products, Crissier, Switzerland) and this test is not specific for single filarial species, and detects IgG against various filarial nematodes affecting humans.

The investigators reported that the sensitivity of the RDT and of the ELISA were 93.8% (61/65) and 90.8% (59/65), respectively. For the RDT, most of the cross-reactions were observed in patients with M. perstans: 7/37 (18.9%), followed by 1/10 (10%) with hyper-reactive malarial splenomegaly and 1/20 (5%) with schistosomiasis. None of the 27 subjects infected with intestinal nematodes was found positive with this test. The ELISA is meant to be a pan-filarial assay, and reacted extensively with cases of M. perstans (95%), as expected, and also in 11/18 (61.1%) patients with strongyloidiasis and in 3/5 (60%) with hookworm infection.

The authors concluded that the novel lateral flow RDT has proven to be an accurate and user-friendly tool for the diagnosis of L. loa infection. While some cross-reactivity with M. perstans should be taken into account when considering its potential application as a screening tool in endemic areas, on the other hand this new test appears to be promising in the of non-endemic setting, where it could be included in a management algorithm. The study was published on May 26, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Sacro Cuore Don Calabria Hospital
Drugs & Diagnostics for Tropical Diseases
Bordier Affinity Products


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.